Skip to main content
. 2017 Jan 16;8(8):13863–13871. doi: 10.18632/oncotarget.14672

Table 2. Summary ORs and 95% CI of Let-7-KRAS rs712 G > T polymorphisms and cancer risk.

N* T vs. G GT vs. GG TT vs. GG GT+TT vs. GG TT vs. GG+GT
Unadjusted OR 95% CI P I2(%) OR 95% CI P I2(%) OR 95% CI P I2(%) OR 95% CI P I2(%) OR 95% CI P I2(%)
Total 13 1.21 1.03-1.42 0.03 75.8 1.11 0.93-1.31 0.24 62.0 1.61 0.98-2.65 0.06 79.8 1.16 0.96-1.41 0.12 72.8 1.69 1.17-2.42 0.01 67.4
Sensitive analysis# 12 1.30 1.20-1.41 <0.01 33.7 1.18 1.07-1.31 <0.01 0 2.07 1.65-2.59 <0.01 24.8 1.27 1.15-1.41 <0.01 3.2 1.96 1.57-2.44 <0.01 14.8
Location
Digestive system 5 1.41 1.26-1.57 <0.01 0 1.24 1.07-1.43 <0.01 0 2.53 1.86-3.44 <0.01 0 1.36 1.19-1.56 <0.01 0 2.35 1.73-3.19 <0.01 0
Head and neck 3 1.20 0.86-1.67 0.29 70.6 1.09 0.79-1.50 0.61 49.8 1.65 0.82-3.32 0.16 52.7 1.16 0.81-1.67 0.42 64.2 1.58 0.86-2.92 0.14 40.1
Lung 2 0.72 0.34-1.56 0.41 84.1 0.46 0.06-3.59 0.46 93. 0.29 0.06-1.52 0.14 73.9 0.43 0.05-3.41 0.42 94.6 0.63 0.43-0.92 0.02 0
Cervical 2 1.35 0.90-2.02 0.14 75.5 1.21 0.96-1.52 0.11 0 2.20 0.70-6.94 0.18 72.0 1.32 0.93-1.88 0.12 54.8 2.03 0.70-5.90 0.19 68.4
Breast 1 1.06 0.76-1.48 0.73 NA 1.02 0.68-1.52 0.92 NA 1.28 0.45-3.60 0.65 NA 1.04 0.71-1.54 0.83 NA 1.27 0.45-3.55 0.65 NA
Design
HB 12 1.20 1.00-1.43 0.05 77.6 1.09 0.91-1.31 0.34 65.0 1.58 0.92-2.72 0.10 81.4 1.15 0.93-1.41 0.20 74.9 1.68 1.14-2.49 0.01 69.9
PB 1 1.33 0.99-1.78 0.06 NA 1.24 0.85-1.80 0.26 NA 1.94 0.90-4.18 0.09 NA 1.33 0.93-1.89 0.12 NA 1.80 0.84-3.83 0.13 NA
Genotype method
PCR-RFLP 11 1.29 1.18-1.41 <0.01 39.0 1.17 1.05-1.31 <0.01 0 2.06 1.62-2.63 <0.01 31.6 1.26 1.14-1.40 <0.01 10.5 1.96 1.54-2.49 <0.01 22.5
Others 2 0.83 0.31-2.21- 0.71 96.0 0.46 0.06-3.49 0.45 95.7 0.55 0.04-7.79 0.66 96.7 0.46 0.05-4.01 0.48 96.7 1.08 0.35-3.31 0.90 89.6
Adjusted
Total 12 1.32 1.18-1.79 <0.01 45.6 1.20 1.08-1.34 <0.01 0 1.58 0.93-2.70 0.09 82.0 1.12 0.73-1.70 0.61 87.0 1.94 1.26-3.00 <0.01 16.6
Sensitive analysis# 10 1.32 1.18-1.79 <0.01 45.6 1.20 1.08-1.34 <0.01 0 1.99 1.49-2.66 <0.01 32.4 1.39 1.21-1.61 <0.01 21.8 1.94 1.26-3.00 <0.01 16.6
Location
Digestive system 5 1.41 1.27-1.55 <0.01 0 1.30 1.12-1.51 <0.01 0 2.42 1.76-3.33 <0.01 0 1.44 1.16-1.79 <0.01 14.0 2.45 1.44-4.15 <0.01 0
Head and neck 3 1.20 0.86-1.67 0.29 71.2 1.09 0.79-1.51 0.60 50.4 1.65 0.82-3.33 0.16 52.7 1.73 1.12-2.67 0.01 NA NA NA NA NA
Lung 1 NA NA NA NA NA NA NA NA 0.14 0.07-0.29 <0.01 NA 0.15 0.07-0.32 <0.01 NA NA NA NA NA
Cervical 2 1.69 1.22-2.34 <0.01 NA 1.20 0.96-1.51 0.12 0 2.19 0.69-6.96 0.18 72.3 1.32 0.92-1.88 0.13 55.6 1.22 0.57-2.60 <0.01 NA
Breast 1 0.94 0.65-1.35 0.74 NA 0.98 0.66-1.46 0.92 NA 0.78 0.28-2.19 0.64 NA NA NA NA NA NA NA NA NA
Design
HB 11 1.32 1.16-1.50 <0.01 51.6 1.18 1.05-1.31 <0.01 0 1.52 0.86-2.69 0.15 83.3 1.01 0.62-1.65 0.97 88.9 1.85 0.85-4.01 0.12 57.7
PB 1 1.35 1.02-1.79 0.04 NA 1.64 1.08-2.50 0.02 NA 12.56 1.05-6.25 0.04 NA 1.75 1.16-2.65 <0.01 NA 2.08 0.87-4.96 0.10 NA
Genotype method
PCR-RFLP 10 1.31 1.14-1.50 <0.01 49.3 1.19 1.06-1.33 <0.01 3.7 2.00 1.55-2.59 <0.01 39.1 1.39 1.21-1.61 <0.01 21.8 1.94 1.26-3.00 <0.01 16.6
Others 2 1.42 1.21-1.66 <0.01 NA 1.31 0.93-1.84 0.12 NA 0.52 0.04-6.70 0.62 96.6 0.15 0.07-0.32 <0.01 NA NA NA NA NA

* Numbers of comparisons

a Test for heterogeneity

# Sensitive analysis without the report of Hu et al.